NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis $1.22 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.01 (+0.41%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RenovoRx Stock (NASDAQ:RNXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RenovoRx alerts:Sign Up Key Stats Today's Range$1.18▼$1.2650-Day Range$0.77▼$1.2452-Week Range$0.75▼$1.69Volume196,895 shsAverage Volume85,147 shsMarket Capitalization$44.62 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.Read More… RenovoRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreRNXT MarketRank™: RenovoRx scored higher than 53% of companies evaluated by MarketBeat, and ranked 477th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRenovoRx has only been the subject of 2 research reports in the past 90 days.Read more about RenovoRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.72% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently decreased by 15.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.72% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently decreased by 15.18%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.19 News SentimentRenovoRx has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for RenovoRx this week, compared to 1 article on an average week.Search Interest5 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,218.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.13% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Email Address RNXT Stock News HeadlinesRenovoRx's (RNXT) "Buy" Rating Reaffirmed at HC WainwrightMay 20 at 1:51 AM | americanbankingnews.comEarnings call transcript: RenovoRx Q1 2025 revenue exceeds expectationsMay 17, 2025 | investing.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 21, 2025 | Porter & Company (Ad)RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comRenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...May 16, 2025 | finance.yahoo.comLe BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisionsMay 15, 2025 | fr.investing.comTranscription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentesMay 15, 2025 | fr.investing.comRenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comSee More Headlines RNXT Stock Analysis - Frequently Asked Questions How have RNXT shares performed this year? RenovoRx's stock was trading at $1.29 at the start of the year. Since then, RNXT shares have decreased by 5.4% and is now trading at $1.22. View the best growth stocks for 2025 here. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The company earned $0.20 million during the quarter, compared to analyst estimates of $0.23 million. Read the conference call transcript. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. Who are RenovoRx's major shareholders? Top institutional shareholders of RenovoRx include AIGH Capital Management LLC (9.49%), AWM Investment Company Inc. (6.25%), Alyeska Investment Group L.P. (1.88%) and ADAR1 Capital Management LLC (1.31%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms. View institutional ownership trends. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RenovoRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN). Company Calendar Last Earnings5/15/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNXT CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees6Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$11.00 Low Stock Price Target$3.00 Potential Upside/Downside+473.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-205.96% Return on Assets-110.01% Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual Sales$240,000.00 Price / Sales185.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-4.36Miscellaneous Outstanding Shares36,572,000Free Float22,297,000Market Cap$44.62 million OptionableNot Optionable Beta1.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:RNXT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.